1. Home
  2. FSM vs TVTX Comparison

FSM vs TVTX Comparison

Compare FSM & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FSM
  • TVTX
  • Stock Information
  • Founded
  • FSM 1990
  • TVTX 2008
  • Country
  • FSM Canada
  • TVTX United States
  • Employees
  • FSM 2490
  • TVTX N/A
  • Industry
  • FSM Precious Metals
  • TVTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • FSM Basic Materials
  • TVTX Health Care
  • Exchange
  • FSM Nasdaq
  • TVTX Nasdaq
  • Market Cap
  • FSM 1.4B
  • TVTX 1.6B
  • IPO Year
  • FSM N/A
  • TVTX N/A
  • Fundamental
  • Price
  • FSM $4.59
  • TVTX $17.49
  • Analyst Decision
  • FSM Hold
  • TVTX Buy
  • Analyst Count
  • FSM 2
  • TVTX 13
  • Target Price
  • FSM $5.75
  • TVTX $23.46
  • AVG Volume (30 Days)
  • FSM 8.4M
  • TVTX 1.1M
  • Earning Date
  • FSM 11-06-2024
  • TVTX 02-13-2025
  • Dividend Yield
  • FSM N/A
  • TVTX N/A
  • EPS Growth
  • FSM N/A
  • TVTX N/A
  • EPS
  • FSM 0.08
  • TVTX N/A
  • Revenue
  • FSM $1,025,155,000.00
  • TVTX $203,447,000.00
  • Revenue This Year
  • FSM $26.54
  • TVTX $62.17
  • Revenue Next Year
  • FSM N/A
  • TVTX $56.38
  • P/E Ratio
  • FSM $56.43
  • TVTX N/A
  • Revenue Growth
  • FSM 38.19
  • TVTX 57.08
  • 52 Week Low
  • FSM $2.63
  • TVTX $5.12
  • 52 Week High
  • FSM $6.36
  • TVTX $20.33
  • Technical
  • Relative Strength Index (RSI)
  • FSM 43.14
  • TVTX 39.02
  • Support Level
  • FSM $4.51
  • TVTX $17.27
  • Resistance Level
  • FSM $5.34
  • TVTX $19.20
  • Average True Range (ATR)
  • FSM 0.20
  • TVTX 0.72
  • MACD
  • FSM -0.03
  • TVTX -0.29
  • Stochastic Oscillator
  • FSM 10.78
  • TVTX 3.80

About FSM Fortuna Silver Mines Inc (Canada)

Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'Ivoire, Mexico, and Peru.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Share on Social Networks: